Avicanna
TSX:AVCN
Leading Biopharmaceutical Research and Development of Commercialized Cannabinoid-Based Products for Global Markets
Leading Biopharmaceutical Research and Development of Commercialized Cannabinoid-Based Products for Global Markets
The medical cannabis space is seeing a radical transformation. With new regulatory changes and supportive legislative actions, the incorporation of cannabis in the medical and pharmaceutical industries presents the perfect storm of investment opportunities that could completely change the game.
Analysts project the global medical cannabis market to reach upwards of US$44.4 billion by 2025, with a CAGR of 22.9 percent. Leveraging these outstanding expectations, many pharmaceutical giants such as Novartis have already formed strong partnerships with big players in cannabis such as Tilray to develop and distribute medical cannabis in legal jurisdictions worldwide. With the collision of two major economic industries, investing in this unprecedented unity of cannabis and medical markets presents enormous investment upside potential at global scales.
Avicanna (TSX:AVCN) is a Canadian biopharmaceutical company since 2015 focused on evidence-based utility of cannabinoids and the commercialization of its premium branded medical cannabis products. Its expertly engineered vertically integrated business model and diversified and high-margin income streams are comprehensive, internationally scalable and incorporate strategic national partnerships, like Shoppers Drug Mart.
Get access to more exclusive Cannabis Investing Stock profiles here
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â